ARS Pharmaceuticals (SPRY) reported Q4 net income Thursday of $0.48 per diluted share.

Three analysts surveyed by FactSet expected a loss of $0.04.

Revenue for the quarter ended Dec. 31 was $86.6 million.

For full-year 2024, the company reported earnings of $0.08 per diluted share, swinging from a loss of $0.57 a year earlier.

Four analysts polled by FactSet expected a loss of $0.52.

Revenue for the year ended Dec. 31 was $89.1 million, up from $30,000 a year earlier.

As of December 31, 2024, the biopharmaceutical company said it had cash, cash equivalents, and short-term investments of $314.0 million, enough to support its operating plans for at least the next three years, the company said.

Shares of the company were up more than 7% in recent premarket activity.